Pubblicazioni

1: Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli
A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C,
Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P.
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal
growth factor receptor 2-positive operable breast cancer: results of the
randomized phase II CHER-LOB study. J Clin Oncol. 2012 Jun 1;30(16):1989-95. Epub
2012 Apr 9. PubMed PMID: 22493419.

2: Giuliani J, Marzola M, Indelli M, Frassoldati A. [Oncological quality
indicators and Colorectal Cancer Program: data from 2009-2010 of University
Hospital in Ferrara, Italy]. Recenti Prog Med. 2012 Feb;103(2):56-61. doi:
10.1701/1045.11386. Italian. PubMed PMID: 22430748.

3: Cavallotti C, Polino D, Frassoldati A, Ranzi E. Analysis of some reaction
pathways active during cyclopentadiene pyrolysis. J Phys Chem A. 2012 Apr
5;116(13):3313-24. Epub 2012 Mar 21. PubMed PMID: 22394280.

4: Giuliani J, Marzola M, Indelli M, Aliberti C, Sartori S, Lanza G, Lelli G,
Frassoldati A. Gastrointestinal Stromal Tumors and Other Malignancies: a Case
Series. J Gastrointest Cancer. 2012 Feb 19. [Epub ahead of print] PubMed PMID:
22350927.

5: Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E, Conte P. Posterior
reversible encephalopathy syndrome during ipilimumab therapy for malignant
melanoma. J Clin Oncol. 2012 Feb 20;30(6):e76-8. Epub 2011 Dec 27. PubMed PMID:
22203769.

6: Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu
I, Miller J, Schenk N, Neven P. Immediate Administration of Zoledronic Acid
Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With
Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial. Clin Breast
Cancer. 2012 Feb;12(1):40-8. doi: 10.1016/j.clbc.2011.08.002. Epub 2011 Oct 19.
PubMed PMID: 22014381.

7: Guarneri V, Pecchi A, Piacentini F, Barbieri E, Dieci MV, Ficarra G, Tazzioli
G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli
P. Magnetic resonance imaging and ultrasonography in predicting infiltrating
residual disease after preoperative chemotherapy in stage II-III breast cancer.
Ann Surg Oncol. 2011 Aug;18(8):2150-7. Epub 2011 Feb 8. PubMed PMID: 21301969.

8: Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A,
Maiorana A, D'Amico R, Conte P. Predictive and prognostic role of p53 according
to tumor phenotype in breast cancer patients treated with preoperative
chemotherapy: a single-institution analysis. Int J Biol Markers. 2010
Apr-Jun;25(2):104-11. PubMed PMID: 20544688.

9: Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis
G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati
A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M.
Adipose-derived mesenchymal stem cells as stable source of tumor necrosis
factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res.
2010 May 1;70(9):3718-29. Epub 2010 Apr 13. PubMed PMID: 20388793.

10: Grisendi G, Annerén C, Cafarelli L, Sternieri R, Veronesi E, Cervo GL,
Luminari S, Maur M, Frassoldati A, Palazzi G, Otsuru S, Bambi F, Paolucci P,
Pierfranco C, Horwitz E, Dominici M. GMP-manufactured density gradient media for
optimized mesenchymal stromal/stem cell isolation and expansion. Cytotherapy.
2010 Jul;12(4):466-77. PubMed PMID: 20353309.

11: Frassoldati A, Guarneri V, Conte P. The clinical relevance of
endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.
Cancer Biol Ther. 2009 Aug;8(15):1456-8. Epub 2009 Aug 5. PubMed PMID: 19617703.

12: Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D'Amico R, Giovannelli S,
Maiorana A, Jovic G, Conte P. A prognostic model based on nodal status and Ki-67
predicts the risk of recurrence and death in breast cancer patients with residual
disease after preoperative chemotherapy. Ann Oncol. 2009 Jul;20(7):1193-8. Epub
2009 Feb 16. PubMed PMID: 19221152.

13: Guarneri V, Frassoldati A, Bruzzi P, D'Amico R, Belfiglio M, Molino A,
Bertetto O, Cascinu S, Cognetti F, Di Leo A, Pronzato P, Crinó L, Agostara B,
Conte P. Multicentric, randomized phase III trial of two different adjuvant
chemotherapy regimens plus three versus twelve months of trastuzumab in patients
with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast
Cancer. 2008 Oct;8(5):453-6. PubMed PMID: 18952561.

14: Gennari A, De Tursi M, Carella C, Ricevuto E, Orlandini C, Frassoldati A,
Conte P, Bruzzi P, Iacobelli S. Epirubicin plus low-dose trastuzumab in HER2
positive metastatic breast cancer. Breast Cancer Res Treat. 2009
May;115(1):131-6. Epub 2008 Sep 13. PubMed PMID: 18791821.

15: Guarneri V, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C,
Conte P. Preoperative chemotherapy plus lapatinib or trastuzumab or both in
HER2-positive operable breast cancer (CHERLOB Trial). Clin Breast Cancer. 2008
Apr;8(2):192-4. PubMed PMID: 18621618.

16: Bertolini F, De Matteis E, Malavasi N, Rossi G, Venturelli C, Codeluppi M,
Frassoldati A, Conte PF. Pulmonary strongyloidiasis mimicking cancer symptoms: a
case of hyperinfection in a patient with metastatic lung cancer. Am J Clin Oncol.
2008 Jun;31(3):308-9. PubMed PMID: 18525313.

17: Frassoldati A, Guarneri V, Piacentini F, Jovic G, Giovannelli S, Oliva C,
Conte PF. Letrozole versus letrozole plus Lapatinib (GW572016) in
hormone-sensitive, HER2-negative operable breast cancer: a double-blind,
randomized, phase II study with biomarker evaluation
(EGF109077-LAP107692/LETLOB). Clin Breast Cancer. 2008 Feb;8(1):97-100. PubMed
PMID: 18501066.

18: Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A,
Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini
A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Phase
II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with
biomarker evaluation in operable breast cancer. Breast Cancer Res Treat. 2008
Jul;110(1):127-34. Epub 2007 Aug 9. PubMed PMID: 17687648.

19: Conte P, Frassoldati A. Aromatase inhibitors in the adjuvant treatment of
postmenopausal women with early breast cancer: Putting safety issues into
perspective. Breast J. 2007 Jan-Feb;13(1):28-35. Review. PubMed PMID: 17214790.

20: Guarneri V, Frassoldati A, Giovannelli S, Borghi F, Conte P. Primary systemic
therapy for operable breast cancer: a review of clinical trials and perspectives.
Cancer Lett. 2007 Apr 18;248(2):175-85. Epub 2006 Aug 21. Review. PubMed PMID:
16919869.

21: Marotta G, Frassoldati A, Zinzani P, Annino L, Brugiatelli M, Ambrosetti A,
Lenoci M, Federico M, Foa R, Lauria F; Italian Cooperative group for HCL
(ICGHCL). Role of interferon-alpha administration after 2-deoxycoformycin in the
treatment of hairy cell leukemia patients. Eur J Haematol. 2006 Aug;77(2):109-13.
PubMed PMID: 16856905.

22: Maur M, Guarneri V, Frassoldati A, Conte PF. Primary systemic therapy in
operable breast cancer: clinical data and biological fall-out. Ann Oncol. 2006
May;17 Suppl 5:v158-64. Review. PubMed PMID: 16807447.

23: Frassoldati A, Maur M, Guarneri V, Nicolini M, Conte PF. Predictive value of
biologic parameters for primary chemotherapy in operable breast cancer. Clin
Breast Cancer. 2005 Oct;6(4):315-24. Review. PubMed PMID: 16277881.

24: Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis
V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z,
Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research. HER2
overexpression as a predictive marker in a randomized trial comparing adjuvant
cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with
stage I/II breast cancer: long-term results. Clin Breast Cancer. 2005
Aug;6(3):253-9. PubMed PMID: 16137437.

25: Carlini P, Ferretti G, Di Cosimo S, Colella E, Tonachella R, Romiti A, Tomao
S, Frassoldati A, Papaldo P, Fabi A, Ruggeri EM, Cognetti F. Is there a benefit
by the sequence anastrozole-formestane for postmenopausal metastatic breast
cancer women? J Steroid Biochem Mol Biol. 2003 Jul;86(1):107-9. PubMed PMID:
12943750.

26: Roila F, Ballatori E, Patoia L, Palazzo S, Veronesi A, Frassoldati A, Cetto
G, Cinieri S, Goldhirsch A; Drug Utilization Rview Team in Oncology. Adjuvant
systemic therapies in women with breast cancer: an audit of clinical practice in
Italy. Ann Oncol. 2003 Jun;14(6):843-8. PubMed PMID: 12796020.

27: Morabito F, Baldini L, Stelitano C, Luminari S, Frassoldati A, Merli F,
Colombi M, Sabbatini R, Brugiatelli M, Federico M; Gruppo Italiano per lo studio
dei linfomi. Prospective study of indolent non-follicular non-Hodgkin's lymphoma:
validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic
criteria for watch and wait policy. Leuk Lymphoma. 2002 Oct;43(10):1933-8. PubMed
PMID: 12481887.

28: Colozza M, Bisagni G, Mosconi AM, Gori S, Boni C, Sabbatini R, Frassoldati A,
Passalacqua R, Bian AR, Rodinò C, Rondini E, Algeri R, Di Sarra S, De Angelis V,
Cocconi G, Tonato M. Epirubicin versus CMF as adjuvant therapy for stage I and II
breast cancer: a prospective randomised study. Eur J Cancer. 2002
Nov;38(17):2279-88. PubMed PMID: 12441265.

29: Carlini P, Frassoldati A, De Marco S, Casali A, Ruggeri EM, Nardi M, Papaldo
P, Fabi A, Paoloni F, Cognetti F. Formestane, a steroidal aromatase inhibitor
after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole):
is a clinical benefit still achievable? Ann Oncol. 2001 Nov;12(11):1539-43.
PubMed PMID: 11822752.

30: Federico M, Zinzani PL, Frassoldati A, Vinceti M, Modè A, Annino L, Chisesi
T, Pagnucco G, Invernizzi R, Spriano M, Resegotti L, Bendandi M, Damasio EE;
Italian Cooperative Group for the Study of Hairy Cell Leukemia. Risk of second
cancer in patients with hairy cell leukemia: long-term follow-up. J Clin Oncol.
2002 Feb 1;20(3):638-46. PubMed PMID: 11821443.

31: Cantore M, Pederzoli P, Cornalba G, Fiorentini G, Guadagni S, Miserocchi L,
Frassoldati A, Ceravolo C, Smerieri F, Muchmore JH. Intra-arterial chemotherapy
for unresectable pancreatic cancer. Ann Oncol. 2000 May;11(5):569-73. PubMed
PMID: 10907950.

32: Cocconi G, Bisagni G, Bella M, Acito L, Anastasi P, Carpi A, Di Costanzo F,
Frassoldati A, Mosconi A, Borrini A, Buzzi P. Comparison of CMF
(cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing
and a sequential intensification regimen in advanced breast cancer: a prospective
randomized study. Am J Clin Oncol. 1999 Dec;22(6):593-600. PubMed PMID: 10597744.

33: Longo G, Fiorani C, Sacchi S, Callea V, Lombardo M, Federico M, Stelitano C,
Angrilli F, Vallisa D, Gobbi PG, Ilariucci F, Frassoldati A, Petrini M,
Silingardi V. Clinical characteristics, treatment outcome and survival of 36
adult patients with primary anaplastic large cell lymphoma. Gruppo Italiano per
lo Studio dei Linfomi (GISL). Haematologica. 1999 May;84(5):425-30. PubMed PMID:
10329921.

34: Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V.
Changes of biological features in breast cancer cells determined by primary
chemotherapy. Breast Cancer Res Treat. 1997 Jul;44(3):185-92. PubMed PMID:
9266097.

35: Luppi M, Morselli M, Bandieri E, Federico M, Marasca R, Barozzi P, Ferrari
MG, Savarino M, Frassoldati A, Torelli G. Sensitive detection of circulating
breast cancer cells by reverse-transcriptase polymerase chain reaction of maspin
gene. Ann Oncol. 1996 Aug;7(6):619-24. PubMed PMID: 8879377.

36: Gobbi PG, Pieresca C, Frassoldati A, Carotenuto M, Di Renzo N, La Sala A,
Berté R, Avanzini P, Federico M, Silingardi V, Ascari E. Vinblastine, bleomycin,
and methotrexate chemotherapy plus extended-field radiotherapy in early,
favorably presenting, clinically staged Hodgkin's patients: the Gruppo Italiano
per lo Studio dei Linfomi Experience. J Clin Oncol. 1996 Feb;14(2):527-33. PubMed
PMID: 8636767.

37: Silingardi V, Federico M, Cavanna L, Avanzini P, Gobbi PG, Lombardo M,
Carotenuto M, Frassoldati A, Pieresca C, Vallisa D, et al. ProMECE-CytaBOM vs
MACOP-B in advanced aggressive non-Hodgkin's lymphoma: long term results of a
multicenter study of the Italian Lymphoma Study Group (GISL). Leuk Lymphoma. 1995
Apr;17(3-4):313-20. PubMed PMID: 8580801.

38: Federico M, Frassoldati A, Lamparelli T, Foà R, Brugiatelli M, Annino L,
Baldini L, Capnist G, Chisesi T, di Celle PF, et al. Long-term results of alpha
interferon as initial therapy and splenectomy as consolidation therapy in
patients with hairy cell leukemia. Final report from the Italian Cooperative
Group for HCL. Ann Oncol. 1994 Oct;5(8):725-31. PubMed PMID: 7826905.

39: Frassoldati A, Lamparelli T, Federico M, Annino L, Capnist G, Pagnucco G,
Dini E, Resegotti L, Damasio EE, Silingardi V. Hairy cell leukemia: a clinical
review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian
Cooperative Group for Hairy Cell Leukemia. Leuk Lymphoma. 1994
Apr;13(3-4):307-16. Review. PubMed PMID: 7519510.

40: Damasio EE, Frassoldati A. Splenectomy following complete response to alpha
interferon (IFN) therapy in patients with hairy cell leukemia (HCL): results of
the HCL88 protocol. Italian Cooperative Group for the Study of Hairy Cell
Leukemia (ICGHCL). Leuk Lymphoma. 1994;14 Suppl 1:95-8. PubMed PMID: 7820061.

41: Federico M, Frassoldati A, Lamparelli T, Dini E, Resegotti L, Damasio EE.
Hairy cell leukemia: the Italian Cooperative Group experience. Leukemia. 1992
Nov;6 Suppl 4:147-8. PubMed PMID: 1279328.

42: Casolo P, Frassoldati A, Giacò M, Lazzaretti MG, Mosca D, Piccinini L. [A
case of primary non-Hodgkin's lymphoma of the adrenal gland]. Minerva Med. 1991
Nov;82(11):781-5. Review. Italian. PubMed PMID: 1766582.

43: Capnist G, Federico M, Chisesi T, Resegotti L, Pagnucco G, Castoldi GL,
Lamparelli T, Frassoldati A, Guarnaccia C, Leoni P, et al. Should alpha
interferon be used as primary treatment for hairy cell leukemia? Italian
Cooperative Group for Hairy Cell Leukemia. Leuk Res. 1991;15(6):419-26. PubMed
PMID: 1861528.

44: Frassoldati A, Federico M, Barbieri F, Brausi M, Pollastri C, Berri G,
Castagnetti G, Palladini PP, Silingardi V. Methotrexate, vinblastine,
epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced
transitional bladder cancer. Med Oncol Tumor Pharmacother. 1991;8(2):99-103.
PubMed PMID: 1749307.

45: Damasio EE, Federico M, Frassoldati A, Lamparelli T, Annino L, Bernasconi C,
Chisesi T, Foá R, Lauria F, Pagnucco G, et al. Splenectomy after initial therapy
with alpha-IFN in patients with hairy-cell leukemia (HCL): a multi-center study
by the Italian Cooperative Group for HCL. Preliminary results. Eur J Haematol
Suppl. 1990;52:29-31. PubMed PMID: 2279542.

46: Federico M, Chisesi T, Lauria F, Bernasconi C, Capnist G, Castoldi G, Damasio
E, Pagnucco G, Frassoldati A, Resegotti L, et al. Human lymphoblastoid interferon
as initial therapy in hairy cell leukaemia: a multicentre study in
non-splenectomized patients. Italian Cooperative Group for Hairy Cell Leukemia.
Br J Haematol. 1989 May;72(1):54-6. PubMed PMID: 2660901.

47: Frassoldati A, Barbieri F, Piccinini L, Federico M, Silingardi V. [Current
role of chemotherapy in musculo-invasive transitional carcinoma of the bladder].
Minerva Urol Nefrol. 1989 Apr-Jun;41(2):103-8. Review. Italian. PubMed PMID:
2672379.

48: Silingardi V, Davolio-Marani S, Federico M, Piccinini L, Frassoldati A, Sarti
M, Burani A, Canossi G. Bone marrow infiltration in hairy cell leukemia after
interferon therapy detected by magnetic resonance imaging. Eur J Cancer Clin
Oncol. 1989 Feb;25(2):209-13. PubMed PMID: 2702977.

49: Federico M, Frassoldati A, Pagnucco G, Lamparelli T, Capnist G, Chisesi T,
Guarnaccia C, Lauria F, Resegotti L, Rossi G, et al. Human lymphoblastoid
alpha-interferon for hairy cell leukemia. An update of the Italian Cooperative
Group. Bone Marrow Transplant. 1989 Jan;4 Suppl 1:179-81. PubMed PMID: 2653499.

50: Silingardi V, Federico M, Frassoldati A, Barbieri F, Palomba G, Mauri C.
Free-from-failure survival in Hodgkin's disease. Long-term analysis of 148 cases
treated with a MOPP-modified protocol. Acta Haematol. 1989;82(4):179-86. PubMed
PMID: 2511719.

51: Curci G, Frassoldati A, Zioni F, Lasagni D, Malaguti R, Zaniol P, Piccinini
L. Urinary albumin excretion during a moderate physical exercise in healthy
subjects. Panminerva Med. 1988 Jan-Mar;30(1):42-4. PubMed PMID: 3419852.

52: Frassoldati A, Lasagni D, Carafa D, Curci G. [Scintigraphy with
indium-111-oxine in the diagnosis of occult inflammation foci. Personal
contribution]. Minerva Med. 1988 Jan;79(1):61-4. Italian. PubMed PMID: 3124022.

53: Curci G, Frassoldati A, Zioni F, Zaniol P, Piccinini L. Plasma fibronectin in
hemoblastosis. Int J Biol Markers. 1987 May-Aug;2(2):71-4. PubMed PMID: 3451931.

54: Curci G, Zioni F, Frassoldati A. [Therapy of idiopathic thrombocytopenic
purpura]. Clin Ter. 1987 Jan 15;120(1):45-50. Review. Italian. PubMed PMID:
2461827.

55: Zioni F, Pompei G, Frassoldati A, Messerotti A. [Idiopathic
pachydermoperiostitis. Description of a case]. Minerva Med. 1985 Mar
24;76(12):575-8. Italian. PubMed PMID: 3991029.